Nomination Committee appointed at Iconovo AB

At the Annual General Meeting of 17 May 2022, it was resolved that Iconovo shall have a Nomination Committee consisting of four members representing the four largest shareholders as of 30 September each year. If any of the four largest shareholders declines their seat, it will be offered to the next largest shareholder in descending order of shareholding.

The Nomination Committee for the 2027 Annual General Meetings consists of:

Emanuel Stihl, appointed by FSG Fund II AB and Chairman of the Nomination Committee;

Gerald Engström, appointed by Färna Invest AB and Gerald Engström;

Mats Johansson, appointed by Abraxas Holding AB and Mats Johansson;

Jonas Ramstedt, appointed by Landia AB.

The Nomination Committee's overarching responsibility for the 2027 Annual General Meeting is to present suitable candidates for the positions of Board Chair, Board members and auditor(s) of the Company, and to propose their remuneration.

The Nomination Committee shall prepare proposals in the following matters to be submitted to the Annual General Meeting for decision:

proposal for Chair of the AGM,

proposal for the number of AGM-elected Board members and, where applicable, number of auditors,

proposal for remuneration to non-employed members of the Board and to non-employed members of the various committees of the Board,

proposal for remuneration to the auditors,

proposals for election of Board Chair, other members of the Board and, where applicable, auditors,

proposals for guidelines for appointing members to the Nomination Committee and for the Nomination Committee's assignments.

Shareholders who wish to submit proposals to the Nomination Committee can contact the Nomination Committee by email at emanuel@fsg.vc.

In order for the Nomination Committee to process received proposals with sufficient care, these should be received by the Nomination Committee by 2 March 2027.

For more information, please contact:

Emanuel Stihl, Chairman of the Nomination Committee, emanuel@fsg.vc.

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort®. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Tapper Partners AB.

Attachments

Nomination Committee appointed at Iconovo AB